Share issue
March 2018
Oncopeptides has completed a directed share issue of approximately SEK 314 million
March 22, 2018 – Regulatory press release
Oncopeptides AB announces that the Company has successfully completed a directed share issue of approximately SEK 314 million (USD 38 million).
The board of directors of Oncopeptides has, based on the issue authorization granted by the annual general meeting on 18 May 2017, and as indicated in the Company’s press release on March 21, 2018, resolved on a directed share issue of 3,980,000 new shares at a subscription price of SEK 79 per share (the “Issue”), which means that the Company will receive gross proceeds of approximately SEK 314 million.
Oncopeptides intends to carry out a directed share issue
March 21, 2018 – Regulatory press release
Oncopeptides AB announces its intention to execute a directed share issue to Swedish and international institutional investors (the “Issue”). The Company has retained ABG Sundal Collier AB, Carnegie Investment Bank AB (publ), DNB Markets, a part of DNB Bank ASA, and Jefferies International Limited to act as Joint Bookrunners (the “Joint Bookrunners”) in connection with the Issue. The Bookbuilding will start immediately following this announcement.
The subscription price and the total number of new shares in the Issue (the “Issue Shares”) will be determined through an accelerated bookbuild procedure (the “Bookbuilding”), but the number of new shares will not exceed 3,980,000 (i.e. approximately 10 per cent of the currently issued and outstanding number of shares in the Company).